Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 578,200 shares, a drop of 7.5% from the July 15th total of 625,300 shares. Currently, 3.8% of the shares of the company are short sold. Based on an average daily volume of 160,900 shares, the short-interest ratio is presently 3.6 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Immix Biopharma in a report on Monday.
View Our Latest Stock Analysis on Immix Biopharma
Institutional Investors Weigh In On Immix Biopharma
Immix Biopharma Trading Up 0.5 %
Immix Biopharma stock opened at $1.90 on Monday. The firm has a market cap of $50.19 million, a PE ratio of -2.04 and a beta of 0.17. Immix Biopharma has a 12 month low of $1.55 and a 12 month high of $7.75. The stock’s 50 day simple moving average is $2.09 and its two-hundred day simple moving average is $2.49.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.06. On average, equities research analysts forecast that Immix Biopharma will post -0.88 EPS for the current year.
About Immix Biopharma
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Read More
- Five stocks we like better than Immix Biopharma
- Golden Cross Stocks: Pattern, Examples and Charts
- Archer Aviation Stumbles on Q2 Earnings, But Potential Remains
- Conference Calls and Individual Investors
- AST SpaceMobile Surges 50% Space Broadband Cellular Launch Nears
- What is Put Option Volume?
- This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.